# DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

> **NCT04509596** · PHASE1 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C

## Key facts

- **NCT ID:** NCT04509596
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2022-07-07
- **Final completion:** 2022-07-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509596, "DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04509596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*